Patrick Vink Net Worth

Patrick Vink biography

Dr. Patrick V.J.J Vink M.D. serves as Independent Director of the Company. Dr. Vink has served on our board of directors since September 2015. Dr. Vink has been an advisor to the pharmaceutical industry since 2015 and non-executive board member of several companies. Previously, Dr. Vink was employed at Cubist Pharmaceuticals, Inc. Most recently he served as Executive Vice-President and Chief Operating Officer, overseeing all worldwide commercial and technical operations as well as global alliance management and managing the company’s profit and loss. He joined Cubist in 2012 as Senior Vice-president and Head of all International Business Operations. In this role he was responsible for the all business activities in International markets outside USA. Prior to joining Cubist, Dr. Vink served as Senior Vice President, Global Head of Hospital Business and Global Head of Biologics for Mylan Inc. In this role, Dr. Vink managed the global hospital business of the company. He joined Mylan in 2008 and established a number of global functions for the company in Switzerland. Before joining Mylan, Dr. Vink held several leadership positions across the industry, including Head of Global Business Franchise Biopharmaceuticals for Novartis Sandoz; Vice-President International Business for Biogen, Inc.; and Head of Worldwide Marketing, Cardiovascular and Thrombosis for Sanofi-Synthélabo SA. Dr. Vink served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) between 2013 and 2015. Dr. Vink graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his M.B.A. in 1992 from the University of Rochester.

What is the salary of Patrick Vink?

As the Independent Director of Spero Therapeutics Inc, the total compensation of Patrick Vink at Spero Therapeutics Inc is $97,874. There are 10 executives at Spero Therapeutics Inc getting paid more, with Ankit Mahadevia having the highest compensation of $1,785,680.

How old is Patrick Vink?

Patrick Vink is 56, he's been the Independent Director of Spero Therapeutics Inc since 2015. There are 9 older and 10 younger executives at Spero Therapeutics Inc. The oldest executive at Spero Therapeutics Inc is Dr. David A. Melnick M.D., 69, who is the Chief Medical Officer.

What's Patrick Vink's mailing address?

Patrick's mailing address filed with the SEC is C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE, MA, 02139.

Insiders trading at Spero Therapeutics Inc

Over the last 15 years, insiders at Spero Therapeutics Inc have traded over $15,920,732 worth of Spero Therapeutics Inc stock and bought 3,223,281 units worth $44,767,755 . The most active insiders traders include Plc Gsk, Jean Francois Formela a Capital Management, Llc Aqu.... On average, Spero Therapeutics Inc executives and independent directors trade stock every 71 days with the average trade being worth of $122,858. The most recent stock trade was executed by Ankit Mahadevia on 27 August 2024, trading 5,912 units of SPRO stock currently worth $7,981.

What does Spero Therapeutics Inc do?

spero therapeutics is focused on the development of novel therapies to treat highly resistant bacterial infections. the culture at spero is one of respect, action, collaboration and transparency. spero team members are leaders in the field, and have the ability and desire to be a part of a team. at spero, a feeling that we are part of something groundbreaking and innovative fuels our approach.

Spero Therapeutics Inc executives and stock owners

Spero Therapeutics Inc executives and other stock owners filed with the SEC include:

• Ankit Mahadevia,
  President, Chief Executive Officer, Director
• Dr. Ankit Mahadevia M.D., MBA,
  Co-Founder, CEO, Pres & Director
• Cristina Larkin,
  Chief Operating Officer and Chief Commercial Officer
• David Melnick,
  Cheif Medical Officer
• Dr. David A. Melnick M.D.,
  Chief Medical Officer
• Cristina Larkin,
  Chief Operating Officer
• Thomas Parr,
  Chief Scientific Officer
• Cynthia Smith,
  Independent Director
• Milind Deshpande,
  Independent Chairman of the Board
• Frank Thomas,
  Independent Director
• Patrick Vink,
  Independent Director
• John Pottage,
  Independent Director
• Jean-Francois Formela,
  Independent Director
• Sharon Klahre,
  IR Contact Officer
• Scott Jackson,
  Independent Director
• Timothy Keutzer,
  Chief Development Officer
• Stephen DiPalma,
  Chief Financial Officer, Treasurer
• Timothy Keutzer,
  Chief Devel. Officer
• James P. Brady,
  Chief Human Resource Officer
• David Musselman,
  Sr. VP of Sales & Market Access
• Tamara Lynn Joseph L.L.M., J.D.,
  Chief Legal Officer
• Ted Jenkins,
  VP & Head of Investor Relations
• Dr. Thomas R. Parr Jr., Ph.D.,
  Chief Scientific Officer
• Satyavrat Shukla C.F.A.,
  Chief Financial Officer
• David P Southwell,
  Director
• John J Gorman,
  Director
• Jack Fingerhut,
  President
• Allen S Greene,
  Chairman of the Board and CEO
• Lager H Martin,
  Director
• Joel Sendek,
  Chief Financial Officer
• Plc Gsk,
  10% owner
• Joseph R Fish,
  EVP & Chief Technology Officer
• Leonard J Stanley,
  Director
• Vikas Goyal,
  Director
• Casper Breum,
  Director
• Stanley P Wirtheim,
  Chief Financial Officer
• Zohar Ben Dov,
  10% owner
• Esther Rajavelu,
  See Remarks
• Capital Management, Llc Aqu...,
  
• Kathleen Tregoning,
  
• Kamal Hamed,
  Chief Medical Officer
• Sath Shukla,
  CEO & President
• Tamara L Joseph,
  Chief Legal Officer